mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
← catalyst calendarSponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Sites
13
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The Sponsor decided to discontinue development of mRNA-2736 for strategic business reasons.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-15 | estimated | When the study began enrolling |
| Primary completion | 2026-05-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-27 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed or Refractory Multiple Myeloma
Intervention
- Biological: mRNA-2736
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events
measured Up to 1 year
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed